Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma View External Link Categories Peer Reviewed Publications Topics: ABC- type diffuse large B-cell lymphoma DLBCL COO immuno-oncology agents targeted therapeutics
DLBCL 1L—What to Expect beyond R-CHOP? View External Link Categories Peer Reviewed Publications Reviews Topics: 1L therapy; bispecific antibodies CAR-T-cells diffuse large B-cell lymphoma DLBCL COO immuno-oncology agents targeted therapeutics
Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements View External Link Categories Peer Reviewed Publications Topics: BCL6 CD10 diffuse large B-cell lymphoma DLBCL COO immuno-oncology agents IRF4 MUM1 targeted therapeutics